Lupin Limited · NSE:LUPIN
Lupin — Q3 FY2022 Earnings Presentation
14 slides from Lupin's earnings presentation, Feb 4, 2022
Slide 1: Exchange filing cover letter
February 4, 2022 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Q3 FY2022 Investor Presentation. Pursuant to Regulation 3
Slide 2: Investor Presentation Q3 FY22 ending 31st Dec 2021
Investor Presentation Q3 FY22 ending 31st Dec 2021
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Lupin wins two awards at the prestigious India Pharma Awards 2021. • Lupin awarded ‘Masters of Risk in Pharma & Healthcare’ at India Risk Management Awards 7th Edition by CNBC-TV18 • Lupin named ‘Best Researcher of the Year’ at the ETHealthworld.com India Pharmaworld A
Slide 5: Q3 FY2022 Snapshot
Q3 FY2022 Snapshot Important developments Sales (INR mn, YoY Growth) Commercial Nilesh D. Gupta • Launched Lupin Diagnostics in India North Managing Director India, Lupin Limited • Entered into exclusive distribution and marketing America, 14,733, 8% agreement with Biomm SA in Brazil for Pegfilgrast
Slide 6: Strategic Vision – Evolving and Growing Global Pharma Company
Strategic Vision – Evolving and Growing Global Pharma Company Highly scaled and Evolving Core Generics Businesses Innovative Platforms Strong US Generics India Region Other Growth Novel products: Specialty & NCE’s Generics Formulations Markets Foundation Canadian Specialty Platform Growth driven by
Slide 7: Financial Results Review
Financial Results Review
Slide 8: P&L Highlights – Q3 FY 2022
P&L Highlights – Q3 FY 2022 % of % of QoQ % of YoY Amount in INR mn Q3FY22 Q2FY22 Q3FY21 sales sales growth sales growth Net sales 40,875 100.0% 40,034 100.0% 2.1% 39,173 100.0% 4.3% Other operating income 735 1.8% 879 2.2% -16.4% 1001 1.4% -26.6% Total revenue 41,610 101.8% 40,913 102.2% 1.7% 40,17
Slide 9: North America Q3FY22
Q3FY22 38.6 YoY QoQ North America % of Sales 9.4% 10.4% Continuing the momentum Consolidating our position in the US1 US quarterly sales ($ mn) #4 #3 #3 #3 #3 #3 #3 140 5 202 195 120 129 188 184 123 121 120 121 4 100 119 172 109 3 80 60 2 65 63 58 40 51 53 55 50 1 20 0 0 2017-18 2018-19 2019-20 2020
Slide 10: India Business Update
Q3FY22 36.0 YoY QoQ India Business Update % of Sales 7.8% -4.5% Lupin Q3 growth of ~9.5%; but grew across key therapy areas in FY22 India business continues to be robust Lupin Continues to outpace industry growth in Chronic India quarterly Sales (INR bn) CAGR MAT Dec’17 – ’21 Lupin Rank1 16.4 MAT MA
Slide 11: Other Markets
Other Markets • Germany: EUR 8.8 mn sales in Q3 FY22 EU5 Developed • Namuscla® and Tempil® sales have contributed double-digit growth YOY • 4th largest generics player1 Australia • Growth of 22% against industry growth of 5.4%1 • 4th largest Rx generics player2; Market leader in CVS space South Afri
Slide 12: Key Financial Metrics
Key Financial Metrics R&D (INR mn) Capex (INR mn) 3,737 2,787 3,546 3,479 3,427 3,300 1,396 1,451 1,182 1,057 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 R&D (% of Sales) Net debt/ Equity 9.1% 0.18 8.9% 8.8% 8.7% 0.10 8.2% 0.05 (0.02) (0.01) Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY
Slide 13: Lupin Today
Lupin Today Financial Metrics Globally Major Markets Market Cap (5) US$ 5.7 bn 10th 6th 3rd 6th 4th 5th 4th Largest Generic Largest Indian Largest in India Pharma South Africa Largest Largest Revenue (FY21)(6) US$ 2.0 bn company Pharma the US Market Rank2 Generic Rank Branded Gx Australia Gx4 (by gl
Slide 14: THANK YOU
THANK YOU Registered Office Lupin Limited, 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway, Santacruz (East), Mumbai 400 055, India. Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com lupin LupinGlobal LupinWorld Lupin Global